This poster is published under an
open license. Please read the
disclaimer for further details.
Type:
Educational Exhibit
Keywords:
Neuroradiology brain, MR, MR-Diffusion/Perfusion, MR-Spectroscopy, Diagnostic procedure, Lymphoma, Dementia
Authors:
L. Farras Roca1, J. J. Sánchez Fernández1, P. Puyalto2, L. Aja Rodriguez1, A. Pons Escoda1, D. E. Nova Vaca1, M. Pérez Rubiralta1, I. García Duitama1, C. Aguilera Grijalvo1; 1Barcelona/ES, 2Badalona/ES
DOI:
10.1594/ecr2016/C-1355
Background
Primary central nervous system lymphoma (PCNSL) is an unusual form of non-Hodgkin type neoplasm,
which represents 6.2%.
Besides brain,
this tumor can also involve meninges,
eyes and spinal cord.
Its appearance in immunocompetent patients in MRI is characterized by the presence of a unique enhancing mass lesion,
whereas,
in immunocompromized patients the typical MRI finding is the presence of enhancing lesions.
Lymphomatsis cerebri (LC) is a rare PCNSL presenting as diffuse non-mass like lesion of white matter,
similar seen in gliomatosis cerebri,
a rare glial tumor,
and may account for its name.
LC is usually described in immunocompetent patients.
Clinically,
it presents with a rapidly progressive dementia and unsteadiness of gait.
Its appearance in histology,
the vast majority of PCNSL are diffuse large B-cell lymphoma,
the remaining cases are low-grade B-cell (8%),
Burkitt lymphoma (5%) or T-cell lymphoma (2-3%) (Fig.1).
According to the treatment,
resection is usually not considered due to the infiltrative nature of these tumors.
The main treatment in PCNSL is high dose methotrexate-based chemotherapy.
However,
the prognosis of lymphomatous cerebri is worse than that of PCNSL.